The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Dendrimer‐Based Lipid Nanoparticles Deliver Therapeutic FAH mRNA to Normalize Liver Function and Extend Survival in a Mouse Model of Hepatorenal Tyrosinemia Type I
Abstract
mRNA‐mediated protein replacement represents a promising concept for the treatment of liver disorders. Children born with fumarylacetoacetate hydrolase (FAH) mutations suffer from Hepatorenal Tyrosinemia Type 1 (HT‐1) resulting in renal dysfunction, liver failure, neurological impairments, and cancer. Protein replacement therapy using FAH mRNA offers tremendous potential to cure HT‐1, but is currently hindered by the development of effective mRNA carriers that can function in diseased livers. Structure‐guided, rational optimization of 5A2‐SC8 mRNA‐loaded dendrimer lipid nanoparticles (mDLNPs) increases delivery potency of FAH mRNA, resulting in functional FAH protein and sustained normalization of body weight and liver function in FAH −/− knockout mice. Optimization using luciferase mRNA produces DLNP carriers that are efficacious at mRNA doses as low as 0.05 mg kg −1 in vivo. mDLNPs transfect > 44% of all hepatocytes in the liver, yield high FAH protein levels (0.5 mg kg −1 mRNA), and are well tolerated in a knockout mouse model with compromised liver function. Genetically engineered FAH −/− mice treated with FAH mRNA mDLNPs have statistically equivalent levels of TBIL, ALT, and AST compared to wild type C57BL/6 mice and maintain normal weight throughout the month‐long course of treatment. This study provides a framework for the rational optimization of LNPs to improve delivery of mRNA broadly and introduces a specific and viable DLNP carrier with translational potential to treat genetic diseases of the liver.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The therapeutic potential of mRNA-based protein replacement therapies has also been tested in other metabolic disorders in preclinical studies, including hereditary tyrosinaemia type I (HTI)142, acute intermittent porphyria222,223, Fabry disease224,225, Crigler–Najjar syndrome type 1 (ref.226), α1 antitrypsin deficiency227, methylmalonic acidaemia/aciduria228, arginase deficiency229, citrin defic”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [142]
In the citing paper
“The mice were i.v. administrated with hFAH mRNA loaded DLNPs every 3 days for a month, during which hFAH expression was elevated in the liver.[162]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [162]
In the citing paper
“However, long-term use of nitisinone increases the risks of developing hepatic neoplasms and liver failure.[162]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [162]
Citations
Cites
mRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
Toxicity of cationic lipids and cationic polymers in gene delivery
Lv, H., Zhang, S., Wang, B., Cui, S., & Yan, J. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.04.014 · Cited by 2,286
Self-citationRational design of cationic lipids for siRNA delivery
Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1602 · Cited by 1,822
Delivery materials for siRNA therapeutics
Kanasty, R., Dorkin, J. R., Vegas, A., & Anderson, D. (2013) · Nature Materials · doi:10.1038/nmat3765 · Cited by 1,800
Gilleron, J., Querbes, W., Zeigerer, A., Borodovsky, A., Marsico, G., Schubert, U., Manygoats, K., Seifert, S., Andree, C., Stöter, M., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2612 · Cited by 1,681
Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs
Morrissey, D. V., Lockridge, J. A., Shaw, L., Blanchard, K. S., Jensen, K., Breen, W., Hartsough, K. C., Machemer, L., Radka, S. F., Jadhav, V., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1122 · Cited by 1,175
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
Safety and efficacy of RNAi therapy for transthyretin amyloidosis
Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208760 · Cited by 971
Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype
Yin, H., Xue, W., Chen, S., Bogorad, R. L., Benedetti, E., Grompe, M., Koteliansky, V., Sharp, P. A., Jacks, T., & Anderson, D. G. (2014) · Nature Biotechnology · doi:10.1038/nbt.2884 · Cited by 951
Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling
Sahay, G., Querbes, W., Alabi, C., Eltoukhy, A., Sarkar, S., Zurenko, C., Karagiannis, E., Love, K., Chen, D., Zoncu, R., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2614 · Cited by 948
Flagged first, then by citations
Research works printed but not linked: 1
- Wu S. Y., 2014, Sci. Transl. Med., 6, 240
Cited by
Sorted by citations
Items 101–200 of 221
Chan, C., Du, S., Dong, Y., & Cheng, X. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666201126162945 · Cited by 45
Bioorthogonal Swarming: In Situ Generation of Dendrimers
Zhang, Y., Üçüncü, M., Gambardella, A., Baibek, A., Geng, J., Zhang, S., Clavadetscher, J., Litzen, I., Bradley, M., & Lilienkampf, A. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c07869 · Cited by 41
Self-citationDeyhimfar, R., Izady, M., Shoghi, M., Kazazi, M. H., Ghazvini, Z. F., Nazari, H., Fekrirad, Z., & Arefian, E. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e26971 · Cited by 42
Zheng, Q., Qin, F., Luo, R., Jin, C., Huang, H., He, X., Xiao, W., Guo, M., Yang, S., He, S., et al. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202011068 · Cited by 39
Li, M., Li, S., Huang, Y., Chen, H., Zhang, S., Zhang, Z., Wu, W., Zeng, X., Zhou, B., & Li, B. (2021) · Advanced Materials · doi:10.1002/adma.202101707 · Cited by 39
Self-citationResearch Advances of Lipid Nanoparticles in the Treatment of Colorectal Cancer
Zhang, J., Ali, K., & Wang, J. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s466490 · Cited by 38
mRNA and gene editing: Late breaking therapies in liver diseases
Zabaleta, N., Torella, L., Weber, N. D., & González‐Aseguinolaza, G. (2022) · Hepatology · doi:10.1002/hep.32441 · Cited by 39
Safford, H. C., Swingle, K. L., Geisler, H. C., Hamilton, A. G., Thatte, A. S., Ghalsasi, A. A., Billingsley, M. M., Alameh, M., Weissman, D., & Mitchell, M. J. (2023) · Small · doi:10.1002/smll.202303568 · Cited by 39
An overview of lipid constituents in lipid nanoparticle mRNA delivery systems
Wu, S., Lin, L., Shi, L., & Liu, S. (2024) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1978 · Cited by 35
Tailoring Highly Branched Poly(β-amino ester)s for Efficient and Organ-Selective mRNA Delivery
Yong, H., Lin, L., Li, Z., Guo, R. F., Wang, C., Liu, S., & Zhou, D. (2024) · Nano Letters · doi:10.1021/acs.nanolett.4c02440 · Cited by 37
Targeted Delivery of mRNA with Polymer–Lipid Nanoparticles for In Vivo Base Editing
Chen, Q., Chang, Y., He, X., Ding, Y., Wang, R., Luo, R., Yuan, J., Chen, J., Zhong, G., Yang, H. Y., et al. (2025) · ACS Nano · doi:10.1021/acsnano.4c14041 · Cited by 34
Song, J., Zhang, Y., Dai, Y., Hu, J., Zhu, L., Xu, X., Yu, Y., Li, H., Yao, B., & Zhou, H. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b00121 · Cited by 33
Lee, S. M., Cheng, Q., Yu, X., Liu, S., Johnson, L. T., & Siegwart, D. J. (2020) · Angewandte Chemie · doi:10.1002/ange.202013927 · Cited by 33
Self-citationmRNA-based modalities for infectious disease management
Zhang, M., Hussain, A., Yang, H., Zhang, J., Liang, X., & Huang, Y. (2022) · Nano Research · doi:10.1007/s12274-022-4627-5 · Cited by 35
Next-generation materials for RNA–lipid nanoparticles: lyophilization and targeted transfection
Wang, T., Sung, T., Yu, T., Lin, H.-Y., Chen, Y.-H., Zhu, Z.-W., Gong, J., Pan, J., & Higuchi, A. (2023) · Journal of Materials Chemistry B · doi:10.1039/d3tb00308f · Cited by 31
Dual SORT LNPs for multi-organ base editing
Kim, M., Song, E. S., Chen, J. C., Chatterjee, S., Sun, Y., Lee, S. M., Wu, S., Patel, P., Tian, Z., Kantor, A., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02675-z · Cited by 39
Self-citationVignesh, A., Menaka, C., Amal, T. C., Selvakumar, S., & Vasanth, K. (2025) · Next Nanotechnology · doi:10.1016/j.nxnano.2025.100223 · Cited by 28
Intelligent Design of Lipid Nanoparticles for Enhanced Gene Therapeutics
Yuan, Y., Li, Y., Li, G., Lei, L., Huang, X., Li, M., & Yao, Y. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00925 · Cited by 28
Surface modification of lipid nanoparticles for gene therapy
Tafech, B., Mohabatpour, F., & Hedtrich, S. (2023) · The Journal of Gene Medicine · doi:10.1002/jgm.3642 · Cited by 25
RNA-based therapies in liver metabolic diseases
Fontanellas, A., Berraondo, P., Urigo, F., Jericó, D., Martini, P. G. V., Pastor, F., & Avila, M. A. (2025) · Gut · doi:10.1136/gutjnl-2023-331742 · Cited by 31
Zhou, K., Johnson, L. T., Xiong, H., Barrios, S., Minnig, J. T., Yan, Y., Abram, B., Yu, X., & Siegwart, D. J. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b01288 · Cited by 23
Self-citationmRNA-Based Approaches to Treating Liver Diseases
Cacicedo, M. L., Limeres, M. J., & Gehring, S. (2022) · Cells · doi:10.3390/cells11203328 · Cited by 23
Lipo-Xenopeptide Polyplexes for CRISPR/Cas9 based Gene editing at ultra-low dose
Germer, J., Lessl, A.-L., Pöhmerer, J., Grau, M., Weidinger, E., Höhn, M., Yazdi, M., Cappelluti, M. A., Lombardo, A., Lächelt, U., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.04.037 · Cited by 25
Recent Advances in Lipid Nanoparticles: Nucleic Acid Therapeutics and Targeting Strategies
Sarmah, S., Baidya, S., & De, M. (2025) · Small · doi:10.1002/smll.202506812 · Cited by 25
Material Design for Next-Generation mRNA Vaccines Using Lipid Nanoparticles
Higuchi, A., Sung, T., Wang, T., Ling, Q., Kumar, S. S., Hsu, S.-T., & Umezawa, A. (2022) · Journal of macromolecular science. Part C, Reviews in macromolecular chemistry and physics/Journal of macromolecular science. Reviews in macromolecular chemistry and physics · doi:10.1080/15583724.2022.2106490 · Cited by 21
The main battlefield of mRNA vaccine – Tumor immune microenvironment
Li, X., Ma, S., Gao, T., Mai, Y., Song, Z., & Yang, J. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109367 · Cited by 22
Liu, J., Xiao, B., Yang, Y., Jiang, Y., Wang, R., Qi, W. D., Pan, Y., Chen, Y., Wang, H., Fan, J., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c06160 · Cited by 20
El-Mayta, R. D., Padilla, M. S., Billingsley, M. M., Han, X., & Mitchell, M. J. (2023) · Journal of Visualized Experiments · doi:10.3791/64810 · Cited by 23
Numerical operations in living cells by programmable RNA devices
Endo, K., Hayashi, K., & Saito, H. (2019) · Science Advances · doi:10.1126/sciadv.aax0835 · Cited by 19
Yu, X., Liu, S., Cheng, Q., Lee, S. M., Wei, T., Zhang, D., Farbiak, L., Johnson, L. T., Wang, X., & Siegwart, D. J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111914 · Cited by 20
Self-citationStructure–activity relationships of pH-responsive and ionizable lipids for gene delivery
Zou, Y., Zhou, Q., Zhao, Y., Zhi, D., Chen, H., Wang, R., Ju, B., & Zhang, S. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.121596 · Cited by 19
Self-citationCurrent knowledge on the tissue distribution of mRNA nanocarriers for therapeutic protein expression
Zadory, M., Lopez, E., Babity, S., Gravel, S., & Brambilla, D. (2022) · Biomaterials Science · doi:10.1039/d2bm00859a · Cited by 18
In Silico Screening Accelerates Nanocarrier Design for Efficient mRNA Delivery
Henser‐Brownhill, T., Martin, L., Samangouei, P., Ladak, A., Apostolidou, M., Nagel, B., & Kwok, A. (2024) · Advanced Science · doi:10.1002/advs.202401935 · Cited by 18
Ely, A., Singh, P., Smith, T. S., & Arbuthnot, P. B. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.05.010 · Cited by 19
Wang, Y., Tang, J., Yang, Y., Song, H., Fu, J., Gu, Z., & Yu, C. (2019) · Angewandte Chemie · doi:10.1002/ange.201914264 · Cited by 20
Lipid nanoparticle steric stabilization roadmap
Cai, X., Zhai, J., Tran, N. L., Mulet, X., & Drummond, C. J. (2022) · Advances in biomembranes and lipid self-assembly · doi:10.1016/bs.abl.2022.05.003 · Cited by 20
Emerging mRNA Technology for Liver Disease Therapy
Wang, J., Fang, Y., Luo, Z., Wang, J., & Zhao, Y. (2024) · ACS Nano · doi:10.1021/acsnano.4c02987 · Cited by 20
Kim, Y., Chatterjee, S., Robertson, A. L., Guerrero, E. D., Vaidya, A., Wang, X., Lee, S. M., Wei, J., Miller, W. E., Farbiak, L., et al. (2025) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5c00282 · Cited by 18
Self-citationNanoparticle Detection in Biology and Medicine: A Review
Kolesnikova, O. A., Shikvin, D. A., Antonova, A. O., Iureva, A. M., Komedchikova, E. N., Obozina, A. S., Kachan, V., Svetlakova, A. V., Kukushkin, I. D., & Shipunova, V. O. (2025) · Biosensors · doi:10.3390/bios15120809 · Cited by 17
Wang, F., Zhang, M., Tian, M., Lou, J., Pan, L., Gao, X., Zhang, L., Lou, X., Zhu, L., Sheng, Y., et al. (2023) · Nano Research · doi:10.1007/s12274-023-6111-2 · Cited by 16
Cheng, Q., Farbiak, L., Vaidya, A., Guerrero, E. D., Lee, E. E., Rose, E. K., Wang, X., Robinson, J. J., Lee, S. M., Wei, T., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2313009120 · Cited by 17
Self-citationmRNA biotherapeutics landscape for rare genetic disorders
Iyer, V. R., Praveen Reddy., P., Kaduskar, B., Moharir, S. C., & Mishra, R. K. (2024) · Journal of Biosciences · doi:10.1007/s12038-023-00415-6 · Cited by 17
Wang, H., & Cheng, Y. (2025) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.70002 · Cited by 16
Kim, H. J., Kim, A., & Miyata, K. (2021) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2021.100428 · Cited by 14
Structure–Activity Relationship of Ionizable Lipids for siRNA and mRNA Lipid Nanoparticle Design
Lee, S. M., Sun, Y., Chatterjee, S., Xiong, H., Cheng, Q., Wang, X., & Siegwart, D. J. (2025) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.5c00463 · Cited by 14
Self-citationRecent Advances in Messenger Ribonucleic Acid (mRNA) Vaccines and Their Delivery Systems: A Review
Belay, W. Y., Nibret, G., & Aschale, Y. (2023) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s418314 · Cited by 16
Cacicedo, M. L., Weinl-Tenbruck, C., Frank, D., Wirsching, S., Straub, B. K., Hauke, J., Okun, J. G., Horscroft, N., Hennermann, J. B., Zepp, F., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.07.006 · Cited by 14
Zhou, J., Zhou, Z., Wang, Z., Sun, L., Li, F., Tang, Y., Liu, J., Liu, J., Zheng, X., Yu, L., et al. (2024) · Nano Today · doi:10.1016/j.nantod.2024.102610 · Cited by 13
Advances and Strategies in Enhancing mRNA Cancer Vaccines
Zhang, M., Chen, S., Hu, H.-J., Ong, Y., & Ni, Q. (2025) · Advanced Materials · doi:10.1002/adma.202509880 · Cited by 16
Hou, X., Wang, C., Zhong, Y., Wang, L., Kang, D. D., Lubitz, G. S., Xue, Y., Liu, Z., Wang, S., Li, H., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113684 · Cited by 13
The significance of bioengineered nanoplatforms against SARS-CoV-2: From detection to genome editing
Hassanzadeh, P. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119289 · Cited by 13
Wu, Y., Sun, G., Ren, W., Wang, C., Wang, C., Ye, X., Chen, Y., Pang, X., Zhang, Q., Wang, Z. J., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03681-8 · Cited by 15
Development and applications of lipid hydrophilic headgroups for nucleic acid therapy
Ma, W., Fu, X., Zhao, T., Qi, Y., Zhang, S., & Zhao, Y. (2024) · Biotechnology Advances · doi:10.1016/j.biotechadv.2024.108395 · Cited by 12
Self-citationNovel Lipid Nanoparticle (LNP) Delivery Systems Enabling the Advancement of RNA Therapeutics
Zhang, H., Han, S., Zhang, X., Ma, J., Jin, L., Wang, Y., Ma, Y., Ma, T., Yu, F., & Song, G. (2026) · Advanced Healthcare Materials · doi:10.1002/adhm.202505340 · Cited by 11
Jester, M. T., Haley, R. M., Billingsley, M. M., Figueroa‐Espada, C. G., Joseph, R. A., Han, X., & Mitchell, M. J. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101457 · Cited by 13
Novel Gene-Correction-Based Therapeutic Modalities for Monogenic Liver Disorders
Ghasemzad, M., Hashemi, M., Miri-Lavasani, Z., Hossein‐Khannazer, N., Bakhshandeh, H., Gramignoli, R., Alikhani, H. K., Najimi, M., Nikeghbalian, S., & Vosough, M. (2022) · Bioengineering · doi:10.3390/bioengineering9080392 · Cited by 11
Bian, Y., Zhang, Y., Hu, B., Huang, Y., Liang, W., Yuan, Q., Zhang, J., Gao, X., & Su, D. (2024) · Small · doi:10.1002/smll.202401282 · Cited by 10
Sjöberg, M., Olsén, E., Mapar, M., Parkkila, P., Niederkofler, S., Mohammadi, S., Jing, Y., Emilsson, G., Lindfors, L., Agnarsson, B., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2426601122 · Cited by 10
Wang, Z., Liu, X., Jin, J., Liu, X., Liu, C., Xie, F., Wang, X., An, F., Xiao, B., Cheng, H., et al. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202420308 · Cited by 10
Self-citationMagnetic Nanostructures and Stem Cells for Regenerative Medicine, Application in Liver Diseases
da Silva, T. B., Dias, E. A., Cardoso, L. M. D. F., Gama, J. F. G., Alves, L. A., & Henriques‐Pons, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119293 · Cited by 11
Cui, Y. J., Wang, K., Li, J. E., & Wang, B. L. (2019) · Ceramics International · doi:10.1016/j.ceramint.2019.12.055 · Cited by 10
Current advances in non-viral nanoparticle-based gene therapy for effective management of cancer
Dhuri, A., Kanp, T., Rode, K., Bharath, M., Gupta, U., Guru, S. K., & Singh, P. K. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.106083 · Cited by 9
Developing Biomaterial‐Based mRNA Delivery System for Lung Disease Treatment
Gu, Q., Xue, H., Liu, Z., Rao, J., Zeng, L., Zhang, C., Lei, L., & Shi, L. (2025) · Advanced Science · doi:10.1002/advs.202505413 · Cited by 11
Nanobionics: From plant empowering to the infectious disease treatment
Hassanzadeh, P., Atyabi, F., & Dinarvand, R. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.07.028 · Cited by 9
Delivering the Message: Translating mRNA Therapy for Liver Inherited Metabolic Diseases
Gurung, S., Perocheau, D. P. B., Ghosh, R., Hart, S. L., & Baruteau, J. (2025) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.70078 · Cited by 10
Kim, J. G., Xu, J., Lee, D., Song, J., Lee, S., Hong, M., Zhu, J., Zhu, A. T., Patwari, K., Shim, E.-H., et al. (2026) · ACS Nano · doi:10.1021/acsnano.5c19036 · Cited by 8
Safe and Highly Efficient Lipid-Pro-Dexamethasone Nanoparticles for mRNA Delivery and Base Editing
Zong, Y., Zhong, H., Wang, Y., Lin, Y., Zhao, L., Wang, X., Cai, J., Lin, H., Xiao, Y., Wei, T., et al. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.6c01708 · Cited by 8
Self-citationHan, Y., Wang, Y., Gao, X., Lei, Y., Li, Y., & Tang, Z. (2026) · Cancer Nexus · doi:10.1002/cnx2.70021 · Cited by 7
Pawar, S., Pingale, P., Garkal, A., Osmani, R. A. M., Gajbhiye, K. R., Kulkarni, M., Pardeshi, K., Mehta, T. A., & Rajput, A. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.131139 · Cited by 6
Recent strategies for enhanced delivery of mRNA to the lungs
Heiser, B. J., Veyssi, A., & Ghosh, D. (2025) · Nanomedicine · doi:10.1080/17435889.2025.2485669 · Cited by 7
RNA-based nanomedicines and their clinical applications
Su, L.-J., Ji, Z.-H., Xu, M.-X., Zhu, J.-Q., Chen, Y., Qiao, J.-F., Wang, Y., & Lin, Y. (2023) · Nano Research · doi:10.1007/s12274-023-6238-5 · Cited by 7
Shu, S., Liu, X., Xu, M. T., Lin, Y., & Li, R. (2022) · Cancer Nanotechnology · doi:10.1186/s12645-022-00112-3 · Cited by 6
He, Z., Le, Z., Shi, Y., Liu, L., Liu, Z., & Chen, Y. (2023) · Angewandte Chemie · doi:10.1002/ange.202310401 · Cited by 5
Polysorbate 80-containing ionizable lipid nanoparticles for mRNA delivery
Tang, X., Ding, S., Yang, S., Cheng, Y., Liu, H., Chen, K., & Han, X. (2024) · Biomaterials Science · doi:10.1039/d4bm00523f · Cited by 5
Yang, W., Li, S., Yu, S., de Sá, A. G. C., Ita, T. S. S., Liang, T. Q., Forgham, H., Qiao, R., Li, J., Stayton, P. S., et al. (2025) · Biomacromolecules · doi:10.1021/acs.biomac.5c01236 · Cited by 4
Xiao, X., Jia, Y., Shen, M., Pich, A., & Shi, X. (2025) · Advanced Interventional Materials · doi:10.1016/j.advim.2025.100002 · Cited by 4
Self-citationNavigating molecular therapies: The emerging role of mRNA in treating inherited metabolic diseases
Castro-Alpízar, J., Lenderink, M. J., Nieuwenhuis, E. E. S., Kooijmans, S. A. A., & Fuchs, S. A. (2025) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2025.109698 · Cited by 4
mRNA therapy: A new frontier in regenerative medicine
Xue, D., Zhang, Y., Shen, A., Tang, T., Liu, B., & Lv, L. (2025) · Interdisciplinary medicine · doi:10.1002/inmd.20240054 · Cited by 5
Progress in Gene Therapy for Hereditary Tyrosinemia Type 1
Thomas, H., & Carlisle, R. C. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17030387 · Cited by 4
CRISPR-Cas9-Loaded Lipid Nanoparticles: A Promising Strategy for Targeted Gene Editing and Therapy
Ebrahimi-Khezrabad, S., Aghdasia, M., Zare‐Zardini, H., Eslami, H., & Eskandari, F. (2025) · BioNanoScience · doi:10.1007/s12668-025-02094-z · Cited by 5
Oligonucleotide‐Linked Lipid Nanoparticles as a Versatile mRNA Nanovaccine Platform
Im, S. H., Chung, Y., Duskunovic, N., Choi, H., Park, S., & Chung, H. J. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202401868 · Cited by 4
CD5 Deficiency Alters Helper T Cell Metabolic Function and Shifts the Systemic Metabolome
Whitley, K. V., Freitas, C. M. T., Moreno, C. M., Haynie, C., Bennett, J., Hancock, J. C., Cox, T. D., Pickett, B. E., & Weber, K. S. (2022) · Biomedicines · doi:10.3390/biomedicines10030704 · Cited by 5
Survival analysis of Electrical Power Distribution systems using Weibull Regression
Fogliatto, M. S. S., Santos, T. M. D. O., Bessani, M., & Maciel, C. D. (2019) · Anais do 14º Simpósio Brasileiro de Automação Inteligente · doi:10.17648/sbai-2019-111513 · Cited by 4
Moderne Konzepte der Nanobiotechnologie für mRNA‐Abgabesysteme
Wang, Y., & Yu, C. (2020) · Angewandte Chemie · doi:10.1002/ange.202003545 · Cited by 4
RNA ‐Based Therapies for Inherited Metabolic Disorders
Reddy, S. V., Gurung, S., Ghosh, R., Mills, P. B., Baruteau, J., & Zhou, H. (2026) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.70150 · Cited by 5
There and back again: a dendrimer’s tale
Ziemba, B., Borowiec, M., & Pietryga, I. F. (2021) · Drug and Chemical Toxicology · doi:10.1080/01480545.2021.1915327 · Cited by 3
Research progress in mRNA drug modification and delivery systems
Zhou, Z., & Li, X. (2023) · Journal of Zhejiang University (Medical Sciences) · doi:10.3724/zdxbyxb-2023-0101 · Cited by 4
MAGE-3 peptide amphiphile micelle vaccine promote anti-tumor immunity in mice with stomach cancerPreprint
Windberg, J., & Zhang, R. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/609214 · Cited by 3
Zong, Y., Wang, Y., Lin, Y., Li, Q., Li, M., Ren, H., Wang, X., Ma, Q., Yu, X., Hu, R., et al. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.01.002 · Cited by 3
Self-citationDelivery Systems for Therapeutic Genome Editing: Challenges, Innovations, and Future Perspectives
Yang, M., Song, Y., Wang, Z., Chao, K., Li, L., Zhang, X., Duan, X., Yu, C., Xue, R., & Zhao, J. (2026) · MedComm · doi:10.1002/mco2.70791 · Cited by 3
Recent advances in strategies for developing tissue-selective mRNA-LNP technology
Zong, Y., Wei, T., & Cheng, Q. (2023) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2023-0613 · Cited by 2
Self-citationAlibeigi, E., Dehkordi, A. A., Asadian, M., Doosti, A., & Piri-Gharaghie, T. (2024) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-024-10593-y · Cited by 2
RetractedLe, Z., Jiang, Q., Chen, H., He, Z., Tan, R., Liu, H., Wen, Z., Shi, Y., Liu, Z., & Chen, Y. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.154513 · Cited by 3
Kelliher, S., Gamba, S., Weiß, L., Shen, Z., Marchetti, M., Schieppati, F., Scaife, C., Madden, S. F., Bennett, K., Fortune, A., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.23.563619 · Cited by 2
Intratracheal administration: Non-invasive approach for liver-targeted siRNA-LNP delivery
Zong, Y., Meng, L., Wang, X., Du, L., Zheng, S., Zhang, H., Wei, T., Gao, S., & Cheng, Q. (2025) · Nano Research · doi:10.26599/nr.2025.94908267 · Cited by 1
Self-citationOptimizing C14120-based LNPs for in vitro and in vivo mRNA delivery
Song, P., Su, J., Vraa, C. L. K., Gockert, M., Fjelstrup, S., Hager, H., & Kjems, J. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102866 · Cited by 1
Li, L., Wang, M., Ye, X., Liu, Z., Duan, Y., Chen, X., Ouyang, Y., Wu, Q., Sun, M., & Xie, T. (2026) · MedComm · doi:10.1002/mco2.70700 · Cited by 1
Dendrimer-based nanoformulations as drug carriers for cancer treatment
Amreddy, N., Chinnappan, M., Munshi, A., & Ramesh, R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-814657-6.00001-x · Cited by 1
Advances in mRNA Delivery and Clinical Applications
Hu, B., Hussain, A., Liu, Q. L., Weng, Y., & Huang, Y. (2022) · RNA technologies · doi:10.1007/978-3-031-08415-7_13 · Cited by 1
Jino Affrald, R., & Narayan, S. (2022) · Handbook of Animal Models and its Uses in Cancer Research · doi:10.1007/978-981-19-1282-5_52-1 · Cited by 1
Metadata
- Authors
- Cheng, Q., Wei, T., Jia, Y., Farbiak, L., Zhou, K., Zhang, S., Wei, Y., Zhu, H., & Siegwart, D. J.
- Affiliations
- Harold C. Simmons Comprehensive Cancer Center (US)
- The University of Texas Southwestern Medical Center (US)
- Corresponding author
- Siegwart, Daniel J.
- ORCID
- Venue
- Advanced Materials
- Publisher
- Wiley
- Published
- 2018-10-25
- Volume
- 30
- Issue
- 52
- Pages
- e1805308-e1805308
- ISSN
- 0935-9648 (ISSN-L)
- 1521-4095
- OpenAlex
- W2898487406
- Cited by
- 221
- References
- 49
- Citations by year
- 2026: 16 · 2025: 30 · 2024: 36 · 2023: 38 · 2022: 32 · 2021: 30 · 2020: 26 · 2019: 13
- FWCI
- 6.13
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Advanced Materials (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Defense (CA150245P3)
- American Cancer Society (RSG‐17‐012‐01)
- Cancer Prevention and Research Institute of Texas (R1212)
- Welch Foundation (I‐1855)
- National Institutes of Health (R01CA190525)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Polymers and Plastics › Dendrimers and Hyperbranched Polymers
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- fumarylacetoacetate hydrolase, mRNA delivery, liver-directed gene therapy, hepatocyte transfection, hereditary liver disease
- MeSH terms
- Animals, Disease Models, Animal, Hydrolases, Liver, Mice, Inbred C57BL, Mice, Transgenic, Random Allocation, RNA, Messenger, Genetic Therapy, Tyrosinemias, Dendrimers, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
